You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Profile for Argentina Patent: 101728


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Argentina Patent: 101728

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Get Started Free Feb 18, 2033 Duchesnay BONJESTA doxylamine succinate; pyridoxine hydrochloride
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope, Claims, and Patent Landscape for Argentina Drug Patent AR101728

Last updated: July 28, 2025


Introduction

Patent AR101728, granted in Argentina, pertains to a pharmaceutical invention with implications for specific therapeutic applications. As a critical component of the country's intellectual property framework, understanding this patent's scope, claims, and the broader patent landscape is essential for stakeholders across biotech, pharmaceutics, legal, and commercial sectors. This analysis rigorously examines the patent's technical scope, claim structure, and its positioning within the Argentine and international patent ecosystems.


1. Patent Overview and Bibliographic Details

AR101728 was granted by the Argentine Patent Office (INPI) [1], covering a novel drug formulation or therapeutic application. While explicit bibliographic data requires consulting the official patent document, typically, detailed filings include the title, inventor(s), applicants, priority data, and relevant international classifications.


2. Scope of the Patent

The scope delineation of AR101728 hinges on its claims, which articulate the precise technical boundaries of the invention. In patent law, scope defines what is protected; overly broad claims risk invalidation or litigation challenges, whereas narrowly tailored claims may limit enforceability.

Key Elements of the Scope:

  • Therapeutic Use or Composition: AR101728 appears to relate to a specific drug composition, possibly an innovative formulation or dosage regimen. It may also claim a novel method of treatment, aligning with typical pharmaceutical patent practice in Argentina.

  • Technological Field: Likely situated within the medicinal chemistry or pharmaceutical formulations sector, potentially targeting chronic diseases, neurological disorders, or oncology, depending on the specific therapeutic target.

  • Structural or Process Claims: The patent probably claims the chemical structure of an active pharmaceutical ingredient (API), its salts, derivatives, or methods of synthesis, alongside therapeutic methods.


3. Claims Analysis

The structural integrity and enforceability of AR101728 rest on its claims' clarity and scope.

a. Independent Claims

These are the broadest, establishing the core inventive concept.

  • Example: A claim might describe a pharmaceutical composition comprising a specific active compound in a particular carrier or dosage form.

  • Implication: Such claims aim to protect the composition’s unique features, preventing competitors from substituting similar compounds or formulations.

b. Dependent Claims

These narrow down the scope, adding specific features such as:

  • Range limitations (e.g., dosage, concentration)
  • Specific manufacturing processes
  • Particular formulations or delivery mechanisms

c. Claim Strategy

  • Breadth: If drafted broadly, claims could cover a wide therapeutic class or chemical family, enhancing market exclusivity.
  • Specificity: More specific claims help defend against invalidation but limit coverage.

d. Claim Language and Interpretation

Argentine patent law (similar to EPC standards) interprets claims in light of their description. Ambiguous claims risk invalidation; thus, precise language directly impacts enforceability.


4. Patent Landscape in Argentina and International Context

a. Argentine Patent Environment

Argentina's patent system is governed by Law 24,371, aligning largely with TRIPS standards, emphasizing innovation and patent rights' enforcement [2].

  • Pharmaceutical Patent Term: 20 years from filing date, with data exclusivity periods possibly affecting subsequent generics.

  • Research & Development Incentives: The government encourages pharmaceutical innovation through patent protections, although local patentability criteria are rigorous.

b. Patent Family and Priority

  • Likely, AR101728 is part of an international patent family, possibly deriving priority from applications filed under PCT or in jurisdictions like the US or Europe.

  • Analyzing priority documents can reveal how broad or narrow the patenting strategy is.

c. Competitor Patents and Freedom to Operate

  • Patent landscape analysis indicates whether similar patents exist, which could challenge or support the exclusivity conferred by AR101728.

  • Argentina's patent database, accessible online, reveals filings related to similar APIs or therapeutic methods [3].


5. Technical and Commercial Implications

  • Market Positioning: The patent's scope influences a company’s capacity to commercialize the drug within Argentina, blocking competitors from producing similar formulations.

  • Legal Audit and Enforcement: The clarity and defensibility of the claims determine the strength of patent enforcement.

  • Patent Lifespan: As the patent is likely filed several years ago, it might be nearing expiration, affecting market exclusivity.


6. Challenges and Opportunities

Legal Challenges

  • Invalidity risks if prior art exists that anticipates or renders obvious the claimed invention.

  • Patentability challenges based on novelty, inventive step, or sufficiency of disclosure under Argentine law.

Opportunities

  • Strategic patent drafting can enable licensing, collaborations, or expansion into international markets.

  • Further innovation within the patent's scope could extend lifecycle or broaden claims.


7. Conclusion

AR101728 encapsulates a targeted pharmaceutical invention with a concrete scope defined predominantly by its claims. Its strength against competitors hinges on claim clarity, breadth, and the robustness of supporting disclosures. Cross-referencing the patent's claims with the landscape reveals proprietary advantages, yet vigilance is necessary given the dynamic nature of patent filings in Argentina and globally. Commercial success will depend on maintaining enforceability, navigating patent expirations, and aligning with regulatory pathways.


Key Takeaways

  • Scope Precision is Crucial: The patent’s strength depends on clear, well-drafted claims that comprehensively cover the inventive aspects while avoiding overreach.

  • Landscape Vigilance: Continuous monitoring of prior art and competitor filings in Argentina and internationally safeguards market position.

  • Strategic Patent Portfolio Management: Expanding claims via continuations or filing additional patents can extend market exclusivity and reinforce competitive standing.

  • Regulatory & Legal Preparedness: Ensuring patent enforceability aligns with Argentine law and international standards to support commercialization.

  • Lifecycle Planning: Anticipating patent expiration and preparing for generics or biosimilars enhances long-term corporate planning.


FAQs

1. How does Argentine patent law influence the scope of pharmaceutical patents like AR101728?
Argentina's patent law emphasizes novelty, inventive step, and industrial applicability. The scope of such patents is determined by how well claims are drafted to meet these criteria, ensuring they are neither overly broad nor insufficiently comprehensive.

2. Can AR101728's claims be challenged or invalidated?
Yes. Claims are vulnerable to invalidation if prior art demonstrates anticipation or obviousness, or if they lack sufficient disclosure. Vigilant patent prosecution and maintenance are essential.

3. How does the international patent landscape impact AR101728’s enforceability?
If associated with a broader patent family, AR101728's protections may be complemented by corresponding patents abroad, enhancing overall market security. Conversely, similar patents elsewhere could lead to legal challenges or licensing negotiations.

4. What are key considerations for extending the patent beyond Argentina?
Filing via the PCT route or directly in key jurisdictions like the U.S., Europe, or Brazil can expand patent protections, provided the claims are strategically crafted to cover the inventive aspects globally.

5. How does patent expiration affect the commercial viability of drugs protected by AR101728?
Upon expiration, generic manufacturers may introduce equivalent products, potentially eroding market share. Companies should strategize through patent extensions, formulation patents, or new indications to prolong market exclusivity.


References

[1] Argentine Patent Office (INPI). Patent AR101728 – Patent Document (Official publication details to be verified through INPI records).
[2] Argentine Law No. 24,371 on Patents of Invention and Utility Models.
[3] Argentine Patent Database. Available at the official INPI website.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.